1. Home
  2. ALTI vs CLLS Comparison

ALTI vs CLLS Comparison

Compare ALTI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AlTi Global Inc.

ALTI

AlTi Global Inc.

HOLD

Current Price

$3.79

Market Cap

407.2M

Sector

Finance

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.07

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTI
CLLS
Founded
2020
1999
Country
United States
France
Employees
490
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
407.2M
384.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ALTI
CLLS
Price
$3.79
$4.07
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.33
AVG Volume (30 Days)
143.6K
37.9K
Earning Date
05-11-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
41.11
N/A
EPS
N/A
N/A
Revenue
$254,956,000.00
N/A
Revenue This Year
$18.06
N/A
Revenue Next Year
$10.71
$0.62
P/E Ratio
N/A
N/A
Revenue Growth
23.21
N/A
52 Week Low
$2.96
$1.33
52 Week High
$5.45
$5.48

Technical Indicators

Market Signals
Indicator
ALTI
CLLS
Relative Strength Index (RSI) 49.89 63.19
Support Level $3.73 $3.93
Resistance Level $3.95 $4.46
Average True Range (ATR) 0.21 0.21
MACD 0.06 0.12
Stochastic Oscillator 75.33 71.16

Price Performance

Historical Comparison
ALTI
CLLS

About ALTI AlTi Global Inc.

AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: